Article Data

  • Views 332
  • Dowloads 141

Original Research

Open Access

CD24 expression is a poor prognostic marker in endometrial carcinoma

  • N. Karahan1
  • M. Giiney2,*,
  • B. Oral2
  • N. Kapucuoglu1
  • T. Mungan2

1Department of Pathology, Faculty of Medicine, Siileyman DemirelI University, lsparta, Turkey

2Department of Obstetrics and Gynecology, Faculty of Medicine, Siileyman DemirelI University, lsparta, Turkey

DOI: 10.12892/ejgo200605500 Vol.27,Issue 5,September 2006 pp.500-504

Published: 10 September 2006

*Corresponding Author(s): M. Giiney E-mail:

Abstract

Objective: CD24 is a cell adhesion molecule that has been implicated in metastatic tumor progression of various solid tumors. Its expression is known to be related to the prognosis of several kinds of tumors. This study was designed to examine the prognostic significance of CD24 in endometrial cancer patients.

Methods: Forty-four endometrial carcinoma tissues were immunostained for CD24 antibody (Ab2, clone 24 C02). Cytoplasmic and membranous immunoreactivity were scored semiquantitatively by Fisher's exact test.

Results: CD24 expression was detected in 34 (77.3%) out of 44 cases. Membranous and cytoplasmic staining of CD24 was significantly associated with the International Federation of Gynecology and Obstetrics (FIGO) grade (p = 0.011 and p = 0.002, respectively) and nodal status (p = 0.002 and p = 0.000, respectively).

Conclusion: Our data suggests that CD24 expression in endometrial carcinoma as detected by immunohistochemistry might be a new marker for a more aggressive endometrial cancer biology. CD24 is commonly up-regulated in endometrial cancer and this corroborates the importance of CD24 in tumor progression among these cases.

Keywords

CD24; Endometrial carcinoma; Immunohistochemistry

Cite and Share

N. Karahan,M. Giiney,B. Oral,N. Kapucuoglu,T. Mungan. CD24 expression is a poor prognostic marker in endometrial carcinoma . European Journal of Gynaecological Oncology. 2006. 27(5);500-504.

References

[1] Ronnett B.M., Zaino R.J., Ellenson L.H., Kurman R.J.: "Endometrial carcinoma". In: Kurman R.J. (ed.) Blaustein's Pathology of the Female Genital Tract. New York, Springer-Verlag, 2001, 501.

[2] American Cancer Society: "Cancer Facts and Figures 2006". Atlanta, GA: American Cancer Society, 2006, 14.

[3] Homesley H.D., Zaino R.: "Endometrial cancer: prognostic factors". Semin. Oneal., 1994, 21, 71.

[4] Mikuta J.J.: "International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988". Cancer, 1993, 71,460.

[5] Akashi T., Shirasawa T., Hirokawa K.: "Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines". Virchows Arch., 1994, 425, 399.

[6] Pirruccello S.J., LeBien T.W.: "The human B-cell associated antigen CD24 is a single chain sialoglycoprotein". J. lmmunol., 1986, 136, 3779.

[7] Nesti A., Von Stein O.D., Zatloukal K. et al.: "Gene expression patterns associated with the metastatic phenotype in rodent and human tumors". Cancer Res., 2001, 61, 1569.

[8] Jackson D., Waibel R., Weber E., Bell J., Stahel R.A.: "CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas". Cancer Res., 1992, 52, 5264.

[9] Fogel M., Friederichs J., Zeller Y. et al.: "CD24 is a marker for human breast carcinoma". Cancer Lett., 1999, 143, 87.

[10] Kristiansen G., Pilarsky C., Pervan J. et al.: "CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer". Prostate, 2004, 58, 183.

[11] Kristiansen G., Denkert C., Schliins K., Dahl E., Pilarsky C., Hauptmann S.: "CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival". Am. J. Pathol., 2002, 161, 1215.

[12] Weichert W., Denkert C., Burkhardt M. et al.: "Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival". Clin. Cancer Res., 2005, 11, 6574.

[13] Aigner S., Ruppert M., Hubbe M. et al.: "Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin". /nt. lmmunol., 1995, 7, 1557.

[14] Aigner S., Ramos C.L., Hafezi-Moghadam A. et al.: "CD24 mediates rolling of breast carcinoma cells on P-selectin". Faseb. J., 1998, 12, 1241.

[15] Lim S.C.: "CD24 and human carcinoma: tumor biological aspects". Biomed. Pharmacother., 2005, 59, 351.

[16] Droz D., Zachar D., Charbit L., Gogusev J., Chretien Y., Iris L.: "Expression of the human nephron differentiation molecules in renal cell carcinoma". Am. J. Pathol., 1990, 137, 895.

[17] Karran L., Jones M., Morley G. et al.: "Expression of a B-cell marker, CD24, on nasophryngeal carcinoma cells". Int. J. Cancer, 1995, 60, 562.

[18] Huang L.R., Hsu H.C.: "Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumour marker gene correlates with p53 mutation and tumour differentiation". Cancer Res., 1995, 55, 4717.

[19] Senner V., Sturm A., Baur I., Schrell U.H., Distel L., Paulus W.: "CD24 promotes invasion of glioma cells in vivo". J. Neuropathol. Exp. Neural., 1999, 58, 795.

[20] Kristiansen G., Sammar M., Altevogt P.: "Tumour biological aspects of CD24a mucin-like adhesion molecule". J. Mo/. Histology, 2004, 35, 255.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top